Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BIOVIE INC. (BIVI)

BioVie prices $4.74 million registered direct offering and private warrant placement

Neutral Impact 3 of 5 financing

BioVie Inc. agreed on November 3, 2026 to sell shares and pre-funded warrants in a registered direct offering and common warrants in a concurrent private placement, with aggregate gross proceeds of approximately $4.74 million before fees and expenses. The offering closed on November 5, 2026, and the company intends to use the net proceeds for working capital and general corporate purposes. The deal adds shares and dilutive warrants, and the company has agreed to restrictions on new share issuances.

Key points

  • Registered direct offering: 960,000 shares at $1.60 per share plus 2,002,500 pre-funded warrants at $1.5999 each
  • Concurrent private placement: 2,962,500 common warrants exercisable at $1.70 per share, starting six months after issuance
  • Placement agent A.G.P./Alliance Global Partners receives a cash fee of 7.0% of gross proceeds
  • Company and directors and officers agreed to issuance and sale restrictions for 60 days after the November 5, 2026 closing

The filing

CompanyBIOVIE INC. (BIVI)
Form8-K, current report
Filed with the SECNov 6, 2026, 5:10 PM ET
Accession number0001520138-26-000460

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.